The market is pricing in perfect execution with no room for error—any growth miss triggers multiple compression

• Forward P/E: 31.4x
• EPS growth estimate: 38% ($8.73 TTM to $12.07 forward)
• P/FCF: ~52x
• PEG: 1.95
• If EPS growth is 20% instead of 38%, forward P/E on 25x exit multiple gives price target of $377—no upside
• If EPS growth is 15%, forward P/E on 25x gives $347—8% downside
• If EPS growth is 12% (mature medtech), forward P/E on 25x gives $332—12% downside
• Historical PEG range for ISRG at major bottoms: 1.0-1.3
• ISRG has historically grown EPS at roughly 20-25% in normal years, not 38%

↩ rebuts: “Bull's claim that 31.4x forward P/E is 'reasonable' for 38% EPS growth”

The July 200 SMA break was institutional distribution, not liquidity noise—a single-day 14.1% collapse on capitulation volume signals lower prices ahead

• July 17 stock went from $402.33 to $345.42—single-day collapse of 14.1%
• 11.56 million shares traded vs ~2M normal daily volume
• 50 SMA at $388.30 acting as overhead resistance
• Lower band at $344.52, upper band at $412.84
• 10 EMA, 50 SMA, 200 SMA, VWMA all sit above current price—textbook bearish alignment

↩ rebuts: “Bull's claim that being below 200 SMA is a buy signal”

ISRG's own buyback behavior reveals management lacks conviction at current levels—collapsing buybacks are a bearish signal, not a bullish one

• TTM buybacks: ~$3.56 billion
• Q3 2025 buybacks: $1.91B (stock was $500+ range)
• Q1 2026 buybacks: $1.12B (stock was $450+)
• Q2 2026 buybacks: only $320M
• Buyback pace collapsed 83% from peak as stock fell 37%
• ISRG sitting on $5.22B in cash but not deploying it aggressively at these levels

↩ rebuts: “Bull's claim that buybacks represent 'patient accumulation' at attractive prices”

Rising inventory outpacing revenue growth is a classic early-stage demand softening signal that could lead to channel stuffing or write-downs

• Inventory up +22% YoY
• $1.667B → $2.029B
• Revenue growth: 18.5%
• 22% inventory build against 18.5% revenue growth—build is outpacing sales

↩ rebuts: “Bull's framing of inventory build as 'possibly an early signal of accelerating system/instrument shipments'”

As a long-duration growth asset, ISRG faces structural multiple compression when discount rates stay elevated—Polymarket pricing 85% probability of zero Fed cuts in 2026 is a direct mathematical headwind

• Polymarket pricing: 85% probability of zero Fed cuts in 2026
• Risk-free rate: 4.5%+
• +100bps in rates = ~10-15% multiple compression for high-multiple growth stocks
• Stock just had worst year since 2008 in no-cut regime
• YTD performance: -17.5%

↩ rebuts: “Bull's claim that 'earnings power matters more than discount rates'”

Competition is transitioning from announced to deploying—the bear case doesn't need to win today, just by 2027 when procurement contracts renew

• Hugo (Medtronic) got CE Mark
• J&J Ottava had clinical updates in 2025
• Renewal cycles for procurement contracts are slow
• Hospital systems themselves becoming dangerous competitors as margins compress
• US procedure volumes may roll over to low-single-digit growth by the time Penang plant generates revenue

↩ rebuts: “Bull's claim that competition hasn't materialized”

Bear's structural price target of $220-$240 represents 35-40% downside from current levels as multiple compresses from 43x trailing to 25x—still above medtech average

• Target price: $220-$240
• 35-40% downside from current levels
• 200 SMA at $473 acting as overhead resistance
• Multiple compression from 43x trailing to 25x
• Final verdict: SELL/AVOID ISRG